Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;17(8):455-456.
doi: 10.1038/s41571-020-0395-x.

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Emmanuel S Antonarakis  1
Affiliations
Comment

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Emmanuel S Antonarakis. Nat Rev Clin Oncol. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. de Bono J, et al. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28. N Engl J Med. 2020. PMID: 32343890 Clinical Trial.

References

    1. Antonarakis, E. S. A New molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24, 430–432 (2019). - DOI
    1. de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911440 (2020). - DOI - PubMed
    1. Dhawan, M. et al. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist 21, 940–945 (2016). - DOI
    1. Abida, W. et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30 (Suppl. 5), v325–v355 (2019).
    1. Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0394 (2020). - DOI - PubMed

Publication types

LinkOut - more resources